February 12, 2021 -- Starpharma has signed a research agreement with Merck to conduct preclinical research on dendrimer-based antibody-drug conjugates (ADCs) utilizing Starpharma's proprietary DEP dendrimer drug delivery technology.
DEP ADCs exploit the potential of Starpharma's DEP technology to provide enhanced characteristics including greater homogeneity, site specific attachment, and higher antibody ratio, compared to conventional ADC approaches, according to the firm.
In previous preclinical studies, DEP ADCs have shown significant tumor regression and outperformed other approved drugs in human ovarian cancer models. Financial details of the agreement were not disclosed.
Copyright © 2021 scienceboard.net